RxDoctor Payments Data

Amy Kingman, MD

Cardiovascular Disease · Macon, GANPI 1992749659

Payments from drug & device makers

$21,185in general payments, 2019–2025

Across 212 payments — averaging $99.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$16K
  • Abbott$2K
  • Actelion Pharmaceuticals US, Inc.$500
  • Amgen$462
  • Johnson & Johnson$375
  • Boston Scientific$339
  • plus $2K from 16 others

What the payments were for

  • Speaking & faculty fees$14,92070%
  • Food & beverage$5,85628%
  • Education$4092%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,185 in reported general payments places this provider in the 85th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$771,378
Medicare patients
1,507
Services billed
5,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban719$611,708
Repatha SureclickEvolocumab437$412,985
EntrestoSacubitril/Valsartan405$398,375
FarxigaDapagliflozin Propanediol423$307,958
NexlizetBempedoic Acid/Ezetimibe159$156,546
XareltoRivaroxaban160$139,793
Praluent PenAlirocumab104$87,291
VascepaIcosapent Ethyl80$42,221
BrilintaTicagrelor31$32,810
NexletolBempedoic Acid27$31,255
Ezetimibe1,567$29,239
Rosuvastatin Calcium1,774$21,334
Repatha PushtronexEvolocumab17$18,423
Metoprolol Succinate1,379$18,255
Ranolazine ErRanolazine150$16,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$151$611,708719 claims
NovartisEntresto$222$398,375405 claims
AstraZenecaFarxiga, Brilinta$177$340,768454 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$15,582$187,801186 claims
Johnson & JohnsonXarelto$375$139,793160 claims
MerckVerquvo$158$7,92212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →